{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+interferon&page=2", "query": { "intervention": "Pegylated interferon", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+interferon&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T13:33:22.761Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00100581", "title": "Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Hepatitis C" ], "interventions": [ { "name": "Efavirenz", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Lopinavir/ritonavir", "type": "DRUG" }, { "name": "Pegylated interferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Tenofovir disoproxil fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 2, "start_date": null, "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-27T13:33:22.761Z", "location_count": 2, "location_summary": "New York, New York • Dallas, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100581" }, { "nct_id": "NCT03500328", "title": "Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq", "type": "OTHER" }, { "name": "Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 900, "start_date": "2018-05-02", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-09-27T13:33:22.761Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Carmichael", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03500328" }, { "nct_id": "NCT01188772", "title": "Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Placebo to match sofosbuvir", "type": "DRUG" }, { "name": "PEG", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 147, "start_date": "2010-08", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-09-27T13:33:22.761Z", "location_count": 22, "location_summary": "Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01188772" }, { "nct_id": "NCT01259817", "title": "Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Risk Polycythemia Vera", "High Risk Essential Thrombocythemia" ], "interventions": [ { "name": "PEGASYS", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ronald Hoffman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2011-09", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-01-11", "last_synced_at": "2026-09-27T13:33:22.761Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • Palo Alto, California • Washington D.C., District of Columbia + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01259817" }, { "nct_id": "NCT00238329", "title": "PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "PEG-interferon alfa-2b", "type": "BIOLOGICAL" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2001-01", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2013-04-08", "last_synced_at": "2026-09-27T13:33:22.761Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00238329" }, { "nct_id": "NCT00525031", "title": "Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Temozolomide (TMZ)", "type": "DRUG" }, { "name": "Pegylated Interferon Alpha-2b (PGI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2006-08", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2020-09-23", "last_synced_at": "2026-09-27T13:33:22.761Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00525031" }, { "nct_id": "NCT01962441", "title": "SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" }, { "name": "Peg-IFN", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 601, "start_date": "2013-09-24", "completion_date": "2016-07-07", "has_results": true, "last_update_posted_date": "2017-06-20", "last_synced_at": "2026-09-27T13:33:22.761Z", "location_count": 23, "location_summary": "Riverside, California • San Diego, California • San Francisco, California + 19 more", "locations": [ { "city": "Riverside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01962441" }, { "nct_id": "NCT01259856", "title": "Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High Risk Polycythemia Vera", "High Risk Essential Thrombocythemia" ], "interventions": [ { "name": "PEGASYS", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ronald Hoffman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2011-09", "completion_date": "2017-06-30", "has_results": true, "last_update_posted_date": "2019-04-30", "last_synced_at": "2026-09-27T13:33:22.761Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01259856" }, { "nct_id": "NCT00746746", "title": "A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "HyperAcute vaccine", "type": "BIOLOGICAL" }, { "name": "Pegylated Interferon-Alpha 2b", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Ochsner Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 30, "start_date": "2008-06", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2011-01-13", "last_synced_at": "2026-09-27T13:33:22.761Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00746746" }, { "nct_id": "NCT01482403", "title": "A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "boceprevir", "type": "DRUG" }, { "name": "mericitabine", "type": "DRUG" }, { "name": "mericitabine placebo", "type": "DRUG" }, { "name": "boceprevir placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2011-11", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2016-08-05", "last_synced_at": "2026-09-27T13:33:22.761Z", "location_count": 7, "location_summary": "Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more", "locations": [ { "city": "Littleton", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482403" } ] }